The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials
Open accessAbstract
Purpose: Prognostic factor analyses have proven useful in predicting outcome in patients with newly diagnosed malignant glioma. Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially. Patients and Methods: Between 1995 and 2002, 333 adults with recurrent gliomas were enrolled onto 10 phase I or II trials of systemic or local therapy. The studies had similar inclusion criteria and were conducted within the New Approaches to Brain Tumor Therapy CNS Consortium. Ninety-three percent of the patients have died. Cox proportional hazards (PH) regression and recursive partitioning analysis (RPA) were performed to identify prognostic factors. Results: Factors associated with an increased risk of death were increased age, lower Karnofsky performance score (KPS), initial and on-study histologies of glioblastoma multiforme (GBM), corticosteroid use, shorter time from original diagnosis to recurrence, and tumor outside frontal lobe. The final PH model included initial histology of GBM (relative risk [RR] = 2.01), 10-year increase in age (RR = 1.23), KPS less than 80 (RR = 1.54), and corticosteroid use (RR = 1.49). RPA resulted in seven classes. Median survival time was poorest in non-GBM patients with KPS less than 80 or GBM patients, age ≥ 50 years, corticosteroid use (4.4 months; 95% CI, 3.6 to 5.4 months); median survival was best in patients with initial histology other than GBM with KPS ≥ 80 and tumor confined to the frontal lobe (25.7 months; 95% CI, 18.7 to 52.5), and was 7.0 months (95% CI, 6.2 to 8.0 months) for all patients. Conclusion: Initial histology, age, KPS, and corticosteroid use are prognostic for survival in recurrent glioma patients. To allow comparisons across phase II trials, enrollment criteria may need to be restricted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Péus, D., Newcomb, N., & Hofer, S. (2013) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-13-72 · Cited by 440
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
Park, J. K., Hodges, T., Arko, L., Shen, M., Dello Iacono, D., McNabb, A., Olsen Bailey, N., Kreisl, T. N., Iwamoto, F. M., Sul, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0582 · Cited by 359
Fogh, S. E., Andrews, D. W., Glass, J., Curran, W., Glass, C., Champ, C., Evans, J. J., Hyslop, T., Pequignot, E., Downes, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6941 · Cited by 347
Metadata
- Authors
- Carson, K. A., Grossman, S. A., Fisher, J. D., & Shaw, E. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-20
- Volume
- 25
- Issue
- 18
- Pages
- 2601-2606
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100673960
- Cited by
- 205
- References
- 2
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials. https://app.cochat.ai/papers/10.1200/jco.2006.08.1661
- The paper
- Carson, K. A., Grossman, S. A., Fisher, J. D., & Shaw, E. G. (2007). Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.08.1661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.